Status:
COMPLETED
Pioglitazone on Pancreatic Steatosis and Bone Health
Lead Sponsor:
University of Texas Southwestern Medical Center
Collaborating Sponsors:
National Institutes of Health (NIH)
Conditions:
Obesity
Type 2 Diabetes
Eligibility:
All Genders
21-99 years
Phase:
NA
Brief Summary
Randomized, double blind, placebo controlled trial evaluating the effect of pioglitazone on pancreatic fat content and bone turnover markers.
Eligibility Criteria
Inclusion
- Fat level in the pancreas above 4% (measurement done by us with an MRI)
- English speaker
- over 21 years old
Exclusion
- contraindication to MRI
- anemia
- pregnancy or desire to conceive
- use of unapproved medications
- prior pancreatic disease
- use of more then 2 alcoholic drinks every day
Key Trial Info
Start Date :
February 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2013
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT00855010
Start Date
February 1 2009
End Date
December 1 2013
Last Update
December 13 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UT Southwestern Medical Center
Dallas, Texas, United States, 75390